IDH1 and central nervous system cancer: IDH mutations, found in about 3% of primary glioblastoma53, and for 80% of low grade glioma, were predictive of PARP inhibitor sensitivity in a range of clinically relevant models, including primary patient-derived glioma cells54,55.